€59.75
0.17% yesterday
Helsinki, Nov 14, 04:51 pm CET
ISIN
FI0009014377
Symbol
ORNBV

Orion Stock price

€60.00
-8.45 12.34% 1M
+5.30 9.69% 6M
+17.22 40.25% YTD
+14.65 32.30% 1Y
+13.16 28.10% 3Y
+20.86 53.30% 5Y
+27.69 85.68% 10Y
+44.85 296.04% 20Y
Helsinki, Closing price Fri, Nov 14 2025
+0.15 0.25%
ISIN
FI0009014377
Symbol
ORNBV
Industry

New AI Insights on Orion Insights AI Insights on Orion

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
€8.4b
Enterprise Value
€8.5b
Net debt
€87.2m
Cash
€224.2m
Shares outstanding
140.7m
Valuation (TTM | estimate)
P/E
26.9 | 16.9
P/S
5.2 | 4.4
EV/Sales
5.2 | 4.4
EV/FCF
38.4
P/B
8.2
Dividends
DPS
€1.64
Yield 1Y | 5Y
2.7% | 3.6%
Growth 1Y | 5Y
1.2% | 1.8%
Payout 1Y | 3Y
68.9% | 74.0%
Increased
3 Years
Financials (TTM | estimate)
Revenue
€1.6b | €1.9b
EBITDA
- | €562.5m
EBIT
€396.3m | €531.7m
Net Income
€313.3m | €499.1m
Free Cash Flow
€220.8m
Growth (TTM | estimate)
Revenue
14.0% | 24.2%
EBITDA
- | 18.4%
EBIT
-4.9% | 17.0%
Net Income
-5.6% | 51.3%
Free Cash Flow
28.9%
Margin (TTM | estimate)
Gross
59.7%
EBITDA
- | 29.4%
EBIT
24.3%
Net
19.2% | 26.1%
Free Cash Flow
13.6%
Financial Health
Equity Ratio
61.7%
Return on Equity
32.8%
ROCE
33.1%
ROIC
27.4%
Debt/Equity
0.3
More
EPS
€2.2
FCF per Share
€1.6
Short interest
-
Employees
4k
Rev per Employee
€390.0k
Show more

Is Orion a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Orion Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Orion forecast:

12x Buy
86%
1x Hold
7%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Orion forecast:

Buy
86%
Hold
7%
Sell
7%

Financial data from Orion

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1,629 1,629
14% 14%
100%
- Direct Costs 657 657
15% 15%
40%
972 972
14% 14%
60%
- Selling and Administrative Expenses 381 381
16% 16%
23%
- Research and Development Expense 202 202
32% 32%
12%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 396 396
5% 5%
24%
Net Profit 313 313
6% 6%
19%

In millions EUR.

Don't miss a Thing! We will send you all news about Orion directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. It specializes in central nervous system disorders, oncology, and respiratory diseases. The firm's customers are specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. The company was founded by Onni Turpeinen, Eemil Tuurala and Wikki Valkama on September 21, 1917 and is headquartered in Espoo, Finland.

Head office Finland
CEO Aino Hurme
Employees 3,943
Founded 1917
Website www.orionpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today